Cooper S, Spiro SG (2006) Small cell lung cancer: treatment review. Respirology 1:241–248.Cooper S , Spiro SG . 2006 . Small cell lung cancer: Treatment review . Respirology 11 : 241 – 248 .Cooper S, Spiro SG (2006) Small cell lung cancer: treatment review. Respirology 11:241–...
small cell lung cancertreatmentAbstract: Lung cancer was relatively uncommon at the turn of the 20th century, and has increased in prevalence at alarming rates, particularly because of the augmented trend in smoking, so that it is now the most common cause of cancer death in the world. ...
Review article Diseases of the Mediastinum Thoracic Surgery Clinics Journal2009,Thoracic Surgery Clinics Kevin S.ChoeMD, PhD,Joseph K.SalamaMD Small Cell Lung Cancer Small cell lung cancer(SCLC) is an aggressive form of lung cancer with rapid growth, and it commonly metastasizes tomediastinal lymph...
Oncolytic virotherapy is an emerging biotherapeutic platform based on genetic engineering of viruses capable of selectively infecting and replicating withi... SH Thorne,DH Kirn - 《Expert Opin Biol Ther》 被引量: 68发表: 2004年 Treatment of non-small-cell lung cancer: a perspective on the rece...
cell lymphoma, neuroblastoma, and non-small cell lung cancer are a few examples of cancers in which the anaplastic lymphoma kinase (ALK) gene may be altered. When activated in cancer, the cancer cells may develop and proliferate due to these ALK gene alterations. Gene fusions, chromosomal ...
Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone. September 19th 2023 HR+ NSCLC More Common in Women; EGFR, KRAS More Common in HR+ NSCLC ...
Small-cell lung cancer is an aggressive form of lung cancer and has been difficult to treat due to therapy resistance. This Review discusses challenges and recent advances in uncovering molecular changes that allow potentially efficient therapies. Small-
et al. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treat. Rev. 37, 242–9 (2011). 6. Ardizzoni, A., Tiseo, M. & Boni L. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled ...
Background:Randomized trials established topotecan and the combination of adriamycin, cyclophosphamide and vincristine (ACO) as second-line therapy options for small-cell lung cancer. We retrospectively evaluated the outcome of SCLC patients undergoing second-line chemotherapy. Patients and Methods:92 consec...
Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by an exceptionally high proliferative rate, strong predilection for early metastasis and poor prognosis. SCLC is strongly associated with exposure to tobacco carcinogens. Most patients have metastatic disease at dia...